Burzynski Research Institute: Clinical Trials

65 trials sponsored by Burzynski Research Institute, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

39 terminated, 13 completed, 10 withdrawn, 2 not yet recruiting. 62 Phase 2, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 262Terminated 39, Completed 13, Withdrawn 9, Suspended 1
Phase 33Not yet recruiting 2, Withdrawn 1

Follow Burzynski Research Institute: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effect of Antineoplaston Therapy on the QT/QTc Interval In Subjects With Diffuse, Intrinsic, Brainstem Glioma
Radiation, Atengenal, Astugenal - Brain Stem Glioma
Phase 3Not yet recruitingBurzynski Research Institute302027-06-012025-09-19
Study of Antineoplaston Therapy + Radiation vs. Radiation Only in Diffuse, Intrinsic, Brainstem Glioma
Radiation, Atengenal, Astugenal - Brain Stem Glioma
Phase 3Not yet recruitingBurzynski Research Institute922025-10-012025-09-16
A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG)
Antineoplaston therapy (Atengenal + Astugenal) - Diffuse, Intrinsic Pontine Glioma
Phase 2SuspendedBurzynski Research Institute12016-04-132025-09-16
Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma
Temozolomide, ANP Therapy - Optic Nerve Glioma
Phase 3WithdrawnBurzynski Research Institute2011-12-012017-07-26
Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma
Antineoplaston therapy (Atengenal + Astugenal) - CNS Tumor
Phase 2TerminatedBurzynski Research Institute31999-03-012017-07-26
Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia
Antineoplaston therapy (Atengenal + Astugenal) - Waldenstrom Macroglobulinemia
Phase 2WithdrawnBurzynski Research Institute1999-02-182018-02-05
Antineoplaston Therapy in Treating Patients With Meningioma
Antineoplaston therapy (Atengenal + Astugenal) - Meningioma
Phase 2TerminatedBurzynski Research Institute31998-06-012017-08-24
Antineoplaston Therapy in Treating Patients With Non-Hodgkin's Lymphoma
Antineoplaston therapy (Atengenal + Astugenal) - Non Hodgkin Lymphoma
Phase 2TerminatedBurzynski Research Institute51997-10-132021-01-22
Antineoplaston Therapy in Treating Patients With Cancer of the Small Intestine
Antineoplaston therapy (Atengenal + Astugenal) - Small Intestine Cancer
Phase 2TerminatedBurzynski Research Institute11997-08-132017-09-29
Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma
Antineoplaston therapy (Atengenal + Astugenal) - Neuroblastoma
Phase 2TerminatedBurzynski Research Institute31996-12-162017-09-28
Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors
Antineoplaston therapy (Atengenal + Astugenal) - Primitive Neuroectodermal Tumor
Phase 2TerminatedBurzynski Research Institute11996-12-122017-09-29
Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer
Antineoplaston therapy (Atengenal + Astugenal) - Stage IV Prostate Cancer
Phase 2WithdrawnBurzynski Research Institute1996-10-112018-01-31
Antineoplaston Therapy in Treating Patients With Stomach Cancer
Antineoplaston therapy (Atengenal + Astugenal) - Stomach (Gastric) Cancer
Phase 2TerminatedBurzynski Research Institute11996-10-042017-09-29
Antineoplaston Therapy in Treating Children With Brain Tumors
Antineoplaston therapy (Atengenal + Astugenal) - Childhood Brain Tumors
Phase 2CompletedBurzynski Research Institute341996-09-012022-03-07
Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer
Antineoplaston therapy (Atengenal + Astugenal) - Stage IV Adrenocortical Carcinoma
Phase 2TerminatedBurzynski Research Institute61996-08-212018-05-09
Antineoplaston Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
Antineoplaston therapy (Atengenal + Astugenal) - Stage IV Non-small Cell Lung Cancer
Phase 2TerminatedBurzynski Research Institute91996-08-212018-02-05
Antineoplaston Therapy in Treating Children With Low-Grade Astrocytoma
Antineoplaston therapy (Atengenal + Astugenal) - Low Grade Astrocytomas
Phase 2CompletedBurzynski Research Institute111996-07-012023-11-21
Antineoplaston Therapy in Treating Patients With Brain Tumors
Antineoplaston therapy (Atengenal + Astugenal) - Refractory Brain Tumors
Phase 2CompletedBurzynski Research Institute401996-07-012017-08-22
Antineoplaston Therapy in Treating Patients With Soft Tissue Sarcoma
Antineoplaston therapy (Atengenal + Astugenal) - Soft Tissue Sarcoma
Phase 2TerminatedBurzynski Research Institute141996-06-142017-09-29
Antineoplaston Therapy in Treating Patients With Stage IV Cancer of the Cervix and/or Vulva
Antineoplaston therapy (Atengenal + Astugenal) - Cervical Cancer Stage IV, Vulvar Cancer, Stage IV
Phase 2TerminatedBurzynski Research Institute81996-06-032017-09-29

Showing 20 of 65. Sign in to see all of them.

Conditions studied

Astrocytoma (8)  ·  Glioblastoma (5)  ·  Lymphoma, Non-Hodgkin (4)  ·  Neuroectodermal Tumors, Primitive (4)  ·  Prostatic Neoplasms (4)  ·  Breast Neoplasms (3)  ·  Glioma (3)  ·  Lung Neoplasms (3)  ·  Recurrence (3)  ·  Brain Neoplasms (2)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Colonic Neoplasms (2)  ·  Neoplasms (2)  ·  Neurocytoma (2)  ·  Oligodendroglioma (2)

Interventions

antineoplaston A10 (65)  ·  antineoplaston AS 2-1 (61)  ·  Biological Therapy (7)  ·  Complementary Therapies (7)  ·  Radiation (2)  ·  Androgen Antagonists (1)  ·  Drug Therapy (1)  ·  Flutamide (1)  ·  Leuprolide (1)  ·  Methotrexate (1)  ·  Temozolomide (1)  ·  bicalutamide (1)

Countries

United States (62)

Top investigators

Stanislaw R. Burzynski, MD, PhD (62)  ·  Stanislaw R Burzynski, MD, PhD (3)